Inactivation of p16/CDKN2 and p15/MTS2 is associated with prognosis and response to chemotherapy in ovarian cancer - Wikidata - awgldk - TriplyDB

Inactivation of p16/CDKN2 and p15/MTS2 is associated with prognosis and response to chemotherapy in ovarian cancer

Inactivation of p16/CDKN2 and p15/MTS2 is associated with prognosis and response to chemotherapy in ovarian cancer

http://www.wikidata.org/entity/Q28216633

about

sameAs

Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer.Expression of p15INK⁴b and p57KIP² and relationship with clinicopathological features and prognosis in patients with vulvar squamous cell carcinoma.p16 Protein and gigaxonin are associated with the ubiquitination of NFκB in cisplatin-induced senescence of cancer cells.Tumour suppressor genes in chemotherapeutic drug response.Differential p16/INK4A cyclin-dependent kinase inhibitor expression correlates with chemotherapy efficacy in a cohort of 88 malignant pleural mesothelioma patients Methylation of tumor suppressor genes in ovarian cancer.Consortium analysis of 7 candidate SNPs for ovarian cancer.Role of p53 and Rb in ovarian cancer.Candidate gene analysis using imputed genotypes: cell cycle single-nucleotide polymorphisms and ovarian cancer risk.Prognostic significance of several biomarkers in epithelial ovarian cancer: a meta-analysis of published studies.Human amniotic epithelial cells inhibit growth of epithelial ovarian cancer cells via TGF‑β1-mediated cell cycle arrest.CDK4/6 inhibition as maintenance and combination therapy for high grade serous ovarian cancer.

P2860

Q27851620-E8D20CB0-90BA-40B2-B763-0C316026F301 Q34666213-4F4ACB07-BE7C-49BE-B576-97A30A5EA7FB Q34683406-6F6F37E6-41DB-40BE-B6E6-6A102B6C9FE8 Q36083098-1679279C-E5FC-4984-9DEB-7BDCA68C8B4E Q36286635-E71B9435-4D1D-4C5A-AC9E-1DA650BAFFBF Q36386613-53185079-A069-4BF3-AA33-FB12C0DC6CE1 Q37155532-487548FA-E530-464A-9169-B335EDCA7C75 Q37188853-FAE598A3-3D8F-42AC-B658-AAF62AAE4DD2 Q37344880-C9A1BEF5-988C-4393-A88A-3D7B53E56317 Q38099749-DE44DE54-146B-43E4-824B-B324D424E046 Q42378301-0B0C632D-8C69-481A-9A90-5883CA4CAE23 Q52592862-1D3FAB43-3E01-4274-811C-F62165BD17FC

P2860

Inactivation of p16/CDKN2 and p15/MTS2 is associated with prognosis and response to chemotherapy in ovarian cancer

http://www.wikidata.org/entity/Q28216633

description

2002 nî lūn-bûn

@nan

2002 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Inactivation of p16/CDKN2 and ...... chemotherapy in ovarian cancer

@ast

Inactivation of p16/CDKN2 and ...... chemotherapy in ovarian cancer

@en

Inactivation of p16/CDKN2 and ...... chemotherapy in ovarian cancer

@nl

type

label

Inactivation of p16/CDKN2 and ...... chemotherapy in ovarian cancer

@ast

Inactivation of p16/CDKN2 and ...... chemotherapy in ovarian cancer

@en

Inactivation of p16/CDKN2 and ...... chemotherapy in ovarian cancer

@nl

prefLabel

Inactivation of p16/CDKN2 and ...... chemotherapy in ovarian cancer

@ast

Inactivation of p16/CDKN2 and ...... chemotherapy in ovarian cancer

@en

Inactivation of p16/CDKN2 and ...... chemotherapy in ovarian cancer

@nl

P1433

Q28216633-52C1D113-992A-4730-8AA9-8670A5E54D9F

P1476

Q28216633-8239EBE3-FC06-46BC-8D83-77BAB5755CE2

P2093

Q28216633-3F1CC508-77C1-40AE-B9E8-91D91CE69ED3

Q28216633-4B31EDB5-4092-45CA-B16D-1518BF5DC54A

Q28216633-56C350ED-38ED-4967-A24E-E8099392261C

Q28216633-6BE503F8-19B6-452E-8136-6E752BED3E8B

Q28216633-7EA783D4-E5EE-452F-BD44-588E823FF432

Q28216633-B9BA9E6F-0714-4F96-8F39-7FE5EC3B504B

Q28216633-D7557B32-97D7-45D3-AFCE-3F7B8F0BA461

Q28216633-F2D461DF-8B15-4300-841B-2CA8128E930C

P2860

Q28216633-2FA1B932-F4E7-42C9-94E6-F7E69EF0C300

Q28216633-35C957CC-77B7-4159-BF1F-5085ABB73CBF

Q28216633-40C53521-F1A2-4D3A-B563-94C3A320A561

Q28216633-5AD34A24-EB60-443D-B448-F7A749ACD144

Q28216633-89D89FC5-C405-469F-A63D-651680412073

Q28216633-B5A6EA1E-0854-4CD2-A97A-9FB4D6A0D3DE

Q28216633-BEFDF56F-D841-4584-A13D-CEA6B602ABB1

Q28216633-C6977E5D-4C80-4DEC-B578-67EDA4FEB7F2

Q28216633-DF3CD35C-55E4-4506-AD6B-9A3470CB194F

Q28216633-E84F67E0-891B-419B-BA53-474C700BD9AE

P304

Q28216633-C2AE5A6C-87F7-4E64-A95B-EF94513778ED

P31

Q28216633-DAFBA4E5-177C-460B-9282-98ED24F817BE

P356

Q28216633-7550C06A-B478-4973-BDAF-A95E2A6D52BC

P407

Q28216633-6DE3483F-6AE5-4DB8-BF84-FD434842DD21

P433

Q28216633-C0B260F9-8DDC-4D87-9D26-C19A77CA1715

P478

Q28216633-8C40AF38-FB42-431D-8BB2-9F20119047DE

P577

Q28216633-5880740E-C5E3-4913-ACC2-6FB513E85BE9

P5875

Q28216633-B5752382-17DF-40DB-A5D6-E082E335728E

P698

Q28216633-F72476DC-62BF-4D9C-8F0E-B32FE5E517C0

P921

Q28216633-0D9F2441-6A38-4846-AE77-509372C97CC1

Q28216633-3AA2FADE-4FD4-4EAF-9EAC-C62DA7DF5A25

P356

P1433

International Journal of Cancer

P1476

Inactivation of p16/CDKN2 and ...... chemotherapy in ovarian cancer

@en

P2093

Ichiro Nagata

http://www.w3.org/2001/XMLSchema#string

Kazuhiko Uchida

http://www.w3.org/2001/XMLSchema#string

Kazuya Kudoh

http://www.w3.org/2001/XMLSchema#string

Masanao Miwa

http://www.w3.org/2001/XMLSchema#string

Misako Hirai

http://www.w3.org/2001/XMLSchema#string

Sadao Yoshida

http://www.w3.org/2001/XMLSchema#string

Yoshihiro Kikuchi

http://www.w3.org/2001/XMLSchema#string

Yoshihito Ichikawa

http://www.w3.org/2001/XMLSchema#string

P2860

p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest

Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers

A cell cycle regulator potentially involved in genesis of many tumor types

Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma

Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells.

p16INK4 expression is associated with the increased sensitivity of human non-small cell lung cancer cells to DNA topoisomerase I inhibitors.

Inactivation of p16/CDKN2 and p15/MTS2 genes in different histological types and clinical stages of primary ovarian tumors.

Adenovirally transferred p16INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death.

Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population.

Altered expression of gamma-glutamylcysteine synthetase, metallothionein and topoisomerase I or II during acquisition of drug resistance to cisplatin in human ovarian cancer cells.

P304

579-82

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/IJC.10331

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

99

http://www.w3.org/2001/XMLSchema#string

P577

2002-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11377069

http://www.w3.org/2001/XMLSchema#string

P698

11992549

http://www.w3.org/2001/XMLSchema#string

P921